
Wockhardt Limited has informed the Exchange about press release dated 16-Mar-2022 titled National Institutes of Health (NIH), USA to conduct human Phase 1 trial of Wockhardt���s novel once-a-day MDR Gram-negative antibiotic WCK 6777
Filed with NSE · · 3 pages · English
The trial aims to address multidrug-resistant Gram-negative infections and is expected to facilitate patient-centered care. The press release highlights the significance of this development in combating hospital-acquired infections.
Written by 6ix AI from the company’s filing. How 6ix writes summaries

Wockhardt Limited has informed the Exchange about press release dated 16-Mar-2022 titled National Institutes of Health (NIH), USA to conduct human Phase 1 trial of Wockhardt���s novel once-a-day MDR Gram-negative antibiotic WCK 6777
Follow Wockhardt into a list and get an email when it puts out news.
Follow Wockhardt